The Essentials
Expert clinical interview synthesizing RCTs, Cochrane reviews, and practice-based evidence on adult smokers; focus on cessation versus tobacco harm reduction (THR).
Conventional therapies: ~8% quit at 6 months with nicotine patches and ~14% with varenicline; only ~6% remain abstinent at 4 years in trials; nicotine vaping is ≈59% more effective than standard NRT; two in three smokers die prematurely if they continue.
Economic lens: THR can reduce healthcare costs by preventing smoking-related disease and by enabling relapse prevention; affordability and access to safer nicotine are critical.
Impact: Offering a spectrum of safer nicotine products (vapes, heated tobacco, pouches, snus) alongside meds and counseling likely increases quits and reduces relapse—high value for money even when long-term nicotine use is needed.
Equity & policy: Vulnerable groups have lower cessation rates; stigma and misinformation about nicotine block access. Training clinicians and regulating for availability, quality, and fair pricing are essential to narrow health gaps.
Why It Matters
After decades of effort, abstinence-only strategies deliver modest, fragile outcomes. Most people who smoke will try—and fail—many times, often without tailored support or practical tools for relapse prevention.
THR reframes the goal: reduce harm now, even if nicotine continues, by replacing combustion with far safer delivery.This matters for equity. People in precarious conditions face more triggers, less time, and fewer services. Expanding options—while correcting myths about nicotine—aligns clinical care with real lives, not ideal scenarios.
Numbers tell one story; dignity tells another: not everyone wants to quit nicotine, but everyone deserves a safer option.
What Changes in Practice
Health/Regulation – Integrate THR into clinical guidelines; authorize regulated access to quality-assured vapes, pouches, snus, and heated tobacco; scale brief interventions plus follow-up; fund clinician training on dosing, device selection, and relapse prevention; adopt clear, stigma-free language (“dependence” vs. “addiction”).
Industry/Innovation – Incentivize safer-by-design products, nicotine titration ranges, and open systems that enable stepped reductions; enforce product standards, toxicology transparency, and youth safeguards; support pharmacovigilance and real-world effectiveness studies.
Society/Environment – Public campaigns to debunk nicotine myths; prioritize outreach for high-risk groups; smoke-free norms paired with harm-reduction access; reduce tobacco-smoke pollution by accelerating substitution away from combustion.
Scenarios and Next Steps
Short term (1–2 years): Update cessation protocols to include THR; train clinicians on combined therapies (e.g., patch + fast-acting NRT; or meds + vaping); ensure affordable access; create decision aids for shared choice; set up proactive follow-up during the first month post-quit.
Medium term (3–5 years): Integrate THR into national tobacco-control strategies; reimbursement for safer nicotine products and counseling; standardize product quality and labeling; establish surveillance of quit and relapse outcomes across modalities.
Long term (5–10 years): Structural decline in smoking prevalence; cultural shift from abstinence-only to patient-centered risk minimization; measurable reductions in cardiopulmonary morbidity and mortality; narrowed inequalities through equitable access to safer nicotine.
The Takeaway
A pragmatic truth: when quitting combustion is the priority, safer nicotine isn’t the problem—it’s the path.
For Further Reading:
Beyond Willpower: A Conversation with Dr. Colin Mendelsohn
Dr. Mendelsohn, to begin our conversation, I would like you to give us an overview of the current landscape regarding tobacco use and efforts to quit smoking. Based on your clinical and scientific experience, how have the available treatments evolved, and how has the medical community—and society at large—come to perceive this issue? What would you say …
Stop Smoking Start Vaping e-book (free PDF copy)
Stop Smoking Start Vaping paperback and e-book